RU2017104621A3 - - Google Patents

Download PDF

Info

Publication number
RU2017104621A3
RU2017104621A3 RU2017104621A RU2017104621A RU2017104621A3 RU 2017104621 A3 RU2017104621 A3 RU 2017104621A3 RU 2017104621 A RU2017104621 A RU 2017104621A RU 2017104621 A RU2017104621 A RU 2017104621A RU 2017104621 A3 RU2017104621 A3 RU 2017104621A3
Authority
RU
Russia
Application number
RU2017104621A
Other languages
Russian (ru)
Other versions
RU2728867C2 (ru
RU2017104621A (ru
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of RU2017104621A publication Critical patent/RU2017104621A/ru
Publication of RU2017104621A3 publication Critical patent/RU2017104621A3/ru
Application granted granted Critical
Publication of RU2728867C2 publication Critical patent/RU2728867C2/ru

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52Purines, e.g. adenine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14Blood; Artificial blood
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Transplantation (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
RU2017104621A 2011-04-20 2012-04-20 Способ совместного кондиционирования и хемоселекции за один цикл RU2728867C2 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161477440P 2011-04-20 2011-04-20
US61/477,440 2011-04-20

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
RU2013151632A Division RU2611396C2 (ru) 2011-04-20 2012-04-20 Способ совместного кондиционирования и хемоселекции за один цикл

Publications (3)

Publication Number Publication Date
RU2017104621A RU2017104621A (ru) 2018-08-15
RU2017104621A3 true RU2017104621A3 (enExample) 2020-06-04
RU2728867C2 RU2728867C2 (ru) 2020-07-31

Family

ID=47041955

Family Applications (2)

Application Number Title Priority Date Filing Date
RU2017104621A RU2728867C2 (ru) 2011-04-20 2012-04-20 Способ совместного кондиционирования и хемоселекции за один цикл
RU2013151632A RU2611396C2 (ru) 2011-04-20 2012-04-20 Способ совместного кондиционирования и хемоселекции за один цикл

Family Applications After (1)

Application Number Title Priority Date Filing Date
RU2013151632A RU2611396C2 (ru) 2011-04-20 2012-04-20 Способ совместного кондиционирования и хемоселекции за один цикл

Country Status (11)

Country Link
US (1) US9439928B2 (enExample)
EP (3) EP3384912B1 (enExample)
JP (4) JP5997257B2 (enExample)
AU (3) AU2012245269B2 (enExample)
CA (1) CA2861440C (enExample)
DK (1) DK2699247T3 (enExample)
ES (1) ES2672693T3 (enExample)
PL (1) PL2699247T3 (enExample)
RU (2) RU2728867C2 (enExample)
TR (1) TR201808037T4 (enExample)
WO (1) WO2012145723A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9682106B2 (en) * 2011-04-20 2017-06-20 The Regents Of The University Of California Method for combined conditioning and chemoselection in a single cycle
EP3384912B1 (en) * 2011-04-20 2020-11-11 The Regents of The University of California Method for combined conditioning and chemoselection in a single cycle
US20170209447A1 (en) * 2014-08-07 2017-07-27 Nitor Therapeutics Use of PNP Inhibitor to Treat Relapse of Malignancy after Hematopoietic Stem Cell Transplant
US20180140606A1 (en) * 2016-11-18 2018-05-24 Calimmune, Inc. In Vivo Chemoselection with Low Dose Thioguanine
JP6783674B2 (ja) 2017-01-20 2020-11-11 株式会社日立ハイテク 自動分析装置、自動分析装置における廃液方法、及び、三方電磁弁
EP4190339B1 (en) * 2017-07-18 2025-07-02 CSL Behring Gene Therapy, Inc. A modulatable switch for selection of donor modified cells
EP3655534B1 (en) * 2017-07-18 2025-07-16 CSL Behring Gene Therapy, Inc. Compositions and methods for treating beta-hemoglobinopathies
CN111511376B (zh) * 2017-10-09 2025-02-25 斯托瓦斯医学研究所 用于扩增细胞群的方法和组合物
CN113543848A (zh) * 2018-12-23 2021-10-22 美国杰特贝林生物制品有限公司 具有杀伤开关的供体t细胞
WO2020139796A1 (en) * 2018-12-23 2020-07-02 Csl Behring L.L.C. Haematopoietic stem cell-gene therapy for wiskott-aldrich syndrome

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5965126A (en) 1996-03-25 1999-10-12 The Penn State Research Foundation use of mutant alkyltransferases for gene therapy to protect from toxicity of therapeutic alkylating agents
WO1997043900A1 (en) * 1996-05-24 1997-11-27 The President And Fellows Of Harvard College In vivo selection
AU7605796A (en) 1996-11-04 1998-05-29 Saint Jude Children's Research Hospital (in vivo) selection of primitive hematopoietic cells
ATE439137T1 (de) 1997-11-14 2009-08-15 Gen Hospital Corp Behandlung von hämatologischen störungen
GB9904281D0 (en) * 1999-02-24 1999-04-21 Reneuron Ltd Transplantation
US7094885B2 (en) * 1999-07-11 2006-08-22 Neorx Corporation Skeletal-targeted radiation to treat bone-associated pathologies
US20030032003A1 (en) 2000-02-02 2003-02-13 Schiestl Robert H. In vivo selection
CA2428721A1 (en) 2000-11-14 2002-05-23 The General Hospital Corporation Blockade of t cell migration into epithelial gvhd target tissues
US7037900B2 (en) 2001-10-12 2006-05-02 Supergen, Inc. Composition and method for treating graft-versus-host disease
EP3384912B1 (en) * 2011-04-20 2020-11-11 The Regents of The University of California Method for combined conditioning and chemoselection in a single cycle

Also Published As

Publication number Publication date
EP2699247B1 (en) 2018-03-07
AU2018200967A1 (en) 2018-03-01
EP2699247A1 (en) 2014-02-26
AU2012245269B2 (en) 2016-09-29
RU2013151632A (ru) 2015-05-27
EP2699247A4 (en) 2014-11-19
EP3384912B1 (en) 2020-11-11
AU2012245269A1 (en) 2013-12-05
HK1256048A1 (en) 2019-09-13
US9439928B2 (en) 2016-09-13
JP2017008090A (ja) 2017-01-12
WO2012145723A1 (en) 2012-10-26
JP6560332B2 (ja) 2019-08-14
JP2019199476A (ja) 2019-11-21
DK2699247T3 (en) 2018-06-14
RU2728867C2 (ru) 2020-07-31
RU2611396C2 (ru) 2017-02-21
AU2018200967B2 (en) 2019-08-15
CA2861440C (en) 2022-11-15
EP3799876A1 (en) 2021-04-07
JP2014512391A (ja) 2014-05-22
AU2016259368A1 (en) 2016-12-08
JP6799117B2 (ja) 2020-12-09
US20140154225A1 (en) 2014-06-05
EP3384912A1 (en) 2018-10-10
JP6266716B2 (ja) 2018-01-24
ES2672693T3 (es) 2018-06-15
AU2016259368B2 (en) 2017-12-14
RU2017104621A (ru) 2018-08-15
TR201808037T4 (tr) 2018-06-21
JP5997257B2 (ja) 2016-09-28
CA2861440A1 (en) 2012-10-26
JP2018044007A (ja) 2018-03-22
PL2699247T3 (pl) 2018-09-28

Similar Documents

Publication Publication Date Title
BR112013022641A2 (enExample)
BR112013031251A2 (enExample)
BR112013027245A2 (enExample)
BR112013024383A2 (enExample)
BR112013023185A2 (enExample)
BR112013022995A2 (enExample)
BR112013026905A2 (enExample)
BR112013027830A2 (enExample)
AP3853A (enExample)
BR112013026744A2 (enExample)
BR112013023927A2 (enExample)
BR112013027452A2 (enExample)
BR112013024365A2 (enExample)
BR112013028733A2 (enExample)
BR112013027121A2 (enExample)
BR112013024588A2 (enExample)
BR112013031556A2 (enExample)
BR112013026790A2 (enExample)
BR112013032368A2 (enExample)
BR112013032377A2 (enExample)
BR112013032380A2 (enExample)
BR112013027836A2 (enExample)
BR112013018949A2 (enExample)
BR112013026895A2 (enExample)
BR112013027761A2 (enExample)